Catabasis pursues bifunctional mutation-agnostic approach to DMD

Using its safely metabolized and rationally targeted (SMART) linker platform, Catabasis has identified an NF-κB inhibitor—edasalonexent—as a potential Duchenne muscular dystrophy (DMD) treatment. Speaking at the 2017 Biotech Showcase, Dr. Jill Milne, co-founder, president and CEO of Catabasis, describes to Mike Ward, global director of content at Informa Pharma Intelligence’s insights portfolio, the company’s ambitions to pursue a pivotal Phase III trial this year.
Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Jill C. Milne – President and CEO, Catabasis